Abiopharma

(99% Neutral) FREQUENCY THERAPEUTICS, INC. (FREQ) Announces Business Combination

(10% Negative) SIGA TECHNOLOGIES, INC. (SIGA) Announces Delay in made Trials for oral TPOXX® (tecovirimat) Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review

(70% Positive) Agios Pharmaceuticals, Inc. (AGIO) Announces Clinical Development Update

(75% Positive) Reata Pharmaceuticals, Inc. (RETA) Provides Update on serving for various development roles globally

(50% Neutral) Allogene Therapeutics, Inc. (ALLO) Announces New Board Appointment

(75% Positive) Bicycle Therapeutics plc (BCYC) Provides Update on included for Bicycle’s wholly owned oncology pipeline

(10% Negative) Y-MABS THERAPEUTICS, INC. (YMAB) Announces Delay in included Trials for GD2-SADA New York Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(90% Positive) RedHill Biopharma (RDHL) Announces Clinical Development Update (Form 6-K)

(99% Neutral) SESEN BIO, INC. (SESN) Announces Clinical Development Update

(85% Positive) BELLUS Health Inc (the company became a subdivision of the company GSK (NYSE: GSK)) (BLU) Announces Clinical Development Update (Form 6-K)